ISSN: 1083-7159

Journal Home

Journal Guideline

Oncologist Q1 Unclaimed

Oxford University Press United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Oncologist is a journal indexed in SJR in Medicine (miscellaneous) and Oncology with an H index of 189. It has a price of 1260 €. It has an SJR impact factor of 1,991 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,991.

Oncologist focuses its scope in these topics and keywords: cancer, patients, metastatic, treatment, colorectal, weeks, cell, lung, therapy, european, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Cancer Research (Q1) Medicine (miscellaneous) (Q1) Oncology (Q1)

Price

1260 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

1,991

SJR Impact factor

189

H Index

288

Total Docs (Last Year)

1177

Total Docs (3 years)

7319

Total Refs

5323

Total Cites (3 years)

984

Citable Docs (3 years)

4.41

Cites/Doc (2 years)

25.41

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Nature Biomedical Engineering Q1
Journal of Thoracic Oncology Q1
Annual Review of Clinical Psychology Q1
Lancet Digital Health, The Q1
Journal of Experimental Medicine Q1

Compare this journals

Aims and Scope

Best articles by citations

Managing Pulmonary Toxicities Associated with Immunotherapy: A Case Discussion

The Role of Capecitabine, an Oral, Enzymatically Activated Fluoropyrimidine, in the Treatment of Metastatic Breast Cancer

Estimates of Young Breast Cancer Survivors at Risk for Infertility in the U.S.

TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World

Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities

FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation

FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia

Multidisciplinary Management of Breast Cancer During Pregnancy

FDA Drug Approval Summary: Bevacizumab Plus FOLFOX4 as Second-Line Treatment of Colorectal Cancer

Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice

Venous Thromboembolism in Patients with Sarcoma: A Retrospective Study

Diagnostic Value of Next-Generation Sequencing in an Unusual Sphenoid Tumor

SHOW MORE ARTICLES

Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory

Active Specific Immunotherapy Targeting the Wilms' Tumor Protein 1 (WT1) for Patients with Hematological Malignancies and Solid Tumors: Lessons from Early Clinical Trials

Staging of Regional Nodes in AJCC Stage I and II Melanoma:

Breast Camps for Awareness and Early Diagnosis of Breast Cancer in Countries With Limited Resources: A Multidisciplinary Model From Kenya

A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer

Advance Directives, Hospitalization, and Survival Among Advanced Cancer Patients with Delirium Presenting to the Emergency Department: A Prospective Study

Managing Vesicant Extravasations

Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders

Safety of Intravenous and Oral Bisphosphonates and Compliance With Dosing Regimens

The CAIRO and FOCUS Studies: Which Lesson Is to Be Learned?

The Goal of Cancer Treatment

Src Inhibition Is Still a Relevant Target in Pancreatic Cancer